144 related articles for article (PubMed ID: 10539122)
1. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.
LePen C; Wait S; Moutard-Martin F; Dujardin M; Ziégler M
Pharmacoeconomics; 1999 Jul; 16(1):59-69. PubMed ID: 10539122
[TBL] [Abstract][Full Text] [Related]
2. Cost of illness and its predictors for Parkinson's disease in Germany.
Spottke AE; Reuter M; Machat O; Bornschein B; von Campenhausen S; Berger K; Koehne-Volland R; Rieke J; Simonow A; Brandstaedter D; Siebert U; Oertel WH; Ulm G; Dodel R
Pharmacoeconomics; 2005; 23(8):817-36. PubMed ID: 16097843
[TBL] [Abstract][Full Text] [Related]
3. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
[TBL] [Abstract][Full Text] [Related]
4. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
6. Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
Rubenstein LM; DeLeo A; Chrischilles EA
Pharmacoeconomics; 2001; 19(7):729-52. PubMed ID: 11548910
[TBL] [Abstract][Full Text] [Related]
7. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.
Dodel RC; Singer M; Köhne-Volland R; Szucs T; Rathay B; Scholz E; Oertel WH
Pharmacoeconomics; 1998 Sep; 14(3):299-312. PubMed ID: 10186468
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
Dodel RC; Berger K; Oertel WH
Pharmacoeconomics; 2001; 19(10):1013-38. PubMed ID: 11735671
[TBL] [Abstract][Full Text] [Related]
9. Costs of drug treatment in Parkinson's disease.
Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
[TBL] [Abstract][Full Text] [Related]
11. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; Spottke A; Reese JP; Baum E; Klotsche J; Rieke J; Simonow A; Eggert K; Oertel WH; Dodel R
Eur J Neurol; 2010 Sep; 17(9):1156-1163. PubMed ID: 20345926
[TBL] [Abstract][Full Text] [Related]
13. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
[TBL] [Abstract][Full Text] [Related]
15. Costs of Parkinson's disease in eastern Europe: a Czech cohort study.
Winter Y; von Campenhausen S; Brozova H; Skoupa J; Reese JP; Bötzel K; Eggert K; Oertel WH; Dodel R; Ruzicka E
Parkinsonism Relat Disord; 2010 Jan; 16(1):51-6. PubMed ID: 19665915
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations.
Hempel AG; Wagner ML; Maaty MA; Sage JI
Ann Pharmacother; 1998 Sep; 32(9):878-83. PubMed ID: 9762373
[TBL] [Abstract][Full Text] [Related]
17. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
18. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
Fraix V; Houeto JL; Lagrange C; Le Pen C; Krystkowiak P; Guehl D; Ardouin C; Welter ML; Maurel F; Defebvre L; Rougier A; Benabid AL; Mesnage V; Ligier M; Blond S; Burbaud P; Bioulac B; Destée A; Cornu P; Pollak P;
J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):443-9. PubMed ID: 16543519
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
20. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
